<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1527">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05141279</url>
  </required_header>
  <id_info>
    <org_study_id>CESM in breast cancer</org_study_id>
    <nct_id>NCT05141279</nct_id>
  </id_info>
  <brief_title>Accuracy Of Contrast Enhanced Mamography in Predicting Response of Breast Cancer Post Neoadjuvant Chemotherapy</brief_title>
  <official_title>Contrast Enhanced Mamography in Predicting Response of Breast Cancer Post Neoadjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this work to evaluate the accuracy of contrast enhanced spectral mamography in&#xD;
      predicting the response to NAC and assessment of residual disease in breast cancer patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This a prospective series ,will be performed for 50 patients diagnosed by biopsy as breast&#xD;
      cancer who will be scheduled for surgery after completing the full coarse of neoadjuvant&#xD;
      chemotherapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of contrast enhanced spectral mamography in the predicting of pathological response to NAC and assessment residual disease in breast cancer patients</measure>
    <time_frame>Basline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess best imaging modalities in pedict post neoadjuvant response</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Stable</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Partial response</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Moderate response</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <description>Excellent response</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <description>Complete response</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        50 patients who will attend to outpatient surgical and oncology clinicS of Assiut&#xD;
        university and diagnosed by biopsy as breast cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient confirmed diagnosed by early breast cancer decided to received neoadjuvant&#xD;
             treatment&#xD;
&#xD;
          -  locally advanced breast cancer&#xD;
&#xD;
          -  operable metastatic breast cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient not candidate for NAC&#xD;
&#xD;
          -  contrast allergy&#xD;
&#xD;
          -  renal impairment&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>DMAhmed</investigator_full_name>
    <investigator_title>Doaa Mahmoud Ahmed</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

